SciELO - Scientific Electronic Library Online

 
vol.140 issue6Features of adolescents hospitalized for a suicide attempt in a general hospitalRetroperitoneal schwannoma: Report of one case author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

MARTINS, Sandro José; MODESTO DOS SANTOS, Vitorino; THOMMEN TELES, Ludmila  and  ALVES LEITE, Viviane. Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab. Rev. méd. Chile [online]. 2012, vol.140, n.6, pp.763-766. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872012000600010.

Background: We report a 54-year-old woman with an stage IIA (T2N0M0) RE and RP negative and HER2-positive ductal invasive breast cancer who developed a reversible cardiotoxicity associated with chemotherapy. After surgery, she received four cycles of doxorubicin and cyclophosfamide. Later, she used paclitaxel and trastuzumab. At the 7th cycle of trastuzumab, she had symptoms of heart failure with left ventricle ejection fraction = 59%. Trastuzumab dosage was reduced in 25%, and heart function progressively improved. Two years after her discharge, the patient remains asymptomatic. Systolic function of the left ventricle was normal before the initial dosis of trastuzumab, but significantly worsened following the beginning of drug administration. Moreover, a clear improvement of heart function was observed soon after the daily dose of trastuzumab was reduced. Better knowledge of risk factors for cardiotoxicity related to chemotherapy, and longstanding surveillance with serial echocardiograms can avoid more severe cardiotoxicity by chemotherapy.

Keywords : Breast neoplasms; Chemotherapy, adjuvant; drug toxicity; stroke volume; trastuzumab.

        · abstract in Spanish     · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License